Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025Blood

Early flow cytometry-based MRD predicts relapse in intermediate-risk AML from low- and middle-income countries

View Full Paper
Ask AI
Bookmark
Share

Authors

LML MaraniJSJosiane Lilian SchivinatoKPKátia Bórgia Barbosa Pagnano

Discussion

Loading...

Member takes

Overview

Observational analysis showed that early MRD clearance predicts relapse in patients with acute myeloid leukemia, indicating the need for standardized monitoring.

Key Points

  • Early measurable residual disease assessment improves outcomes for intermediate-risk acute myeloid leukemia patients.
  • Among patients, 21% and 12.5% were MRD positive after induction 1 and 2, respectively, indicating effective monitoring strategies.
  • Centralized flow cytometry analysis used daunorubicin in treatment protocols, confirming its feasibility and reproducibility for MRD assessment.
  • Results support integrating standardized MRD protocols in clinical practice, especially where molecular testing is less accessible.

Cite This Study

Marani et al. (2025) studied this question.

synapsesocial.com/papers/69362f6e4fa91c937236e0b0https://doi.org/10.1182/blood-2025-1739
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A compelling case for central pathology review of multiparameter flow cytometry measurable residual disease results in Acute Myeloid Leukemia (AML) clinical trials: Data from the PALG-AML1/2016 multicenter randomized study2025 · 1 citations
  2. 2Post-induction minimal residual disease assessment by flow cytometry and molecular biology enables prognostic stratification of patients with NPM1-mutated Acute Myeloid Leukemia: A dataml registry study.2025
  3. 3B-327 Measurable Residual Disease Monitoring at Acute Myeloid Leukemia Based on Laboratory Data2025
  4. 4Prognostic relevance of multiparameter flow cytometry-based MRD assessment in patients with FLT3-ITD mutated AML considering concomitant mutations including DNMT3A/NPM1/WT1 mutation2025 · 1 citations
  5. 5Flow cytometric and molecular MRD in AML: current methods, clinical applications and challenges2025 · 6 citations